Business & Industry

Novartis has entered into an exclusive global license agreement with BoomRay Pharmaceuticals for an undisclosed preclinical radioligand therapy asset, with total potential payments to BoomRay reaching up to $900 million. Announced on September 22, 2026, this radioligand license deal brings...

The UK's National Institute for Health and Care Research (NIHR) has opened the first funding round for its Strategic Infrastructure Partnerships programme, inviting applications for a share of £45 million aimed at accelerating the translation of early-stage medical discoveries...

Obesity treatment is entering a more competitive phase. Ozempic and Mounjaro helped make GLP-1-based medicines mainstream, but the next wave is looking beyond simply producing weight loss. The opportunity is significant because obesity remains widespread. U.S. data show that 40.3%...

DECHEMA, EEPC INDIA and Messe Frankfurt India brought together more than 200 industry leaders, business stakeholders and professionals from India’s process, chemical, pharmaceutical and engineering sectors at a Networking Evening in New Delhi on 8 September 2026. Held at...

Neuland Laboratories is accelerating its peptide manufacturing expansion, with the first of four planned modules now operational at its commercial peptide manufacturing site in Hyderabad. The company said the newly commissioned module is designed to meet growing customer demand...

A comprehensive survey of 5,000 patients across the United States, the United Kingdom, France, and Germany indicates that pharmaceutical manufacturers have a timely opportunity to build consumer trust through enhanced traceability. With six in 10 respondents voicing concern that...

Danish pharmaceutical company Novo Nordisk and biotechnology developer Orbis Medicines have entered into a drug discovery and licensing agreement valued at up to $1.4 billion to develop oral therapies for cardiometabolic diseases. The program aims to advance oral alternatives...